CG Oncology, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 48.61 million compared to USD 35.44 million a year ago. Basic loss per share from continuing operations was USD 15.65 compared to USD 11.71 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.98 USD | -3.20% | +5.19% | 0.00% |
May. 14 | Goldman Sachs Upgrades CG Oncology to Buy From Neutral With $50 Price Target | MT |
May. 09 | CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
0.00% | 2.06B | |
+33.63% | 50.85B | |
-0.09% | 42.82B | |
+49.62% | 42.03B | |
-4.96% | 29.55B | |
+11.18% | 26.11B | |
-21.95% | 19.13B | |
+8.61% | 13.05B | |
+28.31% | 12.16B | |
+24.73% | 12.08B |
- Stock Market
- Equities
- CGON Stock
- News CG Oncology, Inc.
- CG Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023